Physician profile
Nathaniel Peyton
NPI 1336526938
$3,631.08
in general payments reported to CMS, 2019-2025
24 companies · $1,067 in 2025
The $1,067 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $251 · 2020: $347 · 2021: $455 · 2022: $194 · 2023: $368 · 2024: $948 · 2025: $1,067.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,384.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,383.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $887.10 | 2020-2025 | |
| Janssen Biotech, INC. | $433.83 | 2019-2025 | Tremfya, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $427.67 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $417.05 | 2019-2025 | Entyvio |
| Pfizer INC. | $259.31 | 2020-2025 | |
| Gilead Sciences, INC. | $199.86 | 2019-2025 | |
| Genzyme Corporation | $150.44 | 2023-2025 | |
| Lilly USA, LLC | $135.70 | 2025 | Omvoh |
| Qol Medical, LLC | $115.53 | 2020-2025 | Sucraid |
| Aimmune Therapeutics, INC. | $71.09 | 2024-2025 | Zenpep |
| Cook Medical LLC | $66.56 | 2021 | |
| Merck Sharp & Dohme LLC | $60.84 | 2022-2024 | Dificid |
| Intercept Pharmaceuticals, INC. | $57.76 | 2021-2024 | |
| Ardelyx, INC. | $55.76 | 2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $52.73 | 2023-2024 | Dupixent |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $46.72 | 2024-2025 | Voquezna |
| Celltrion USA INC. | $40.74 | 2024 | Zymfentra |
| Celgene Corporation | $35.51 | 2022-2024 | Zeposia |
| Braintree Laboratories, INC. | $24.52 | 2024 | Sutab, Suflave |
| Biofire Diagnostics, LLC | $22.96 | 2021 | |
| Madrigal Pharmaceuticals | $19.65 | 2024 | Resmetirom |
| Shire North American Group INC | $19.47 | 2019 | |
| Exact Sciences Corporation | $15.27 | 2024 | Cologuard Collection Kit |
| Novo Nordisk INC | $15.01 | 2025 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathaniel Peyton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.